Allied Market Research published a report, titled, “Opioid Induced Constipation (OIC) Drugs Market by Drug Type (Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, Others), by Prescription Type (Over The Counter Drugs, Prescribed Drugs), by Distribution Channel (Hospital Pharmacies, Online Providers, Drug Store and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031.” According to the report, the global opioid induced constipation (OIC) drugs industry generated $1.10 billion in 2021, and is estimated to reach $1.79 billion by 2031 witnessing a CAGR of 4.9% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive scenarios.
Access Sample Data & Findings:
https://www.alliedmarketresearch.com/request-sample/13745
Drivers, Restraints, and Opportunities:
Rise in demand for novel drugs for management of opioid induced constipation (OIC) disorder, rise in adoption of methylnaltrexone (parenteral – subcutaneous) for opioid induced constipation (OIC) treatment, and increase in awareness towards the use of mu-opioid receptor antagonists and chloride channel type-2 activator drive the global opioid induced constipation (OIC) drugs market. However, side effects of using opioid induced constipation (OIC) drugs, high costs of novel pharmaceuticals, and unfavorable reimbursement policies restrict the market growth. On the other hand, rising R&D activities, surge in regulatory approvals, higher spending for opioid induced constipation (OIC) research, and increase in demand for novel therapeutics for treating opioid induced constipation (OIC) will present new growth opportunities for the global meniscus repair system market in the coming years.
Growth & innovations in the pharmaceutical industry for the manufacturing of opioid induced constipation (OIC) drugs owing to massive pool of health-conscious consumers, creates an opportunity for the opioid induced constipation drugs market share. The growth of the opioid induced constipation (OIC) drugs market is expected to be driven by emerging markets, due to availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of chronic pain cases in adults, and surge in demand for novel drugs for management of opioid induced constipation (OIC) disorder. Furthermore, the healthcare industry in emerging economies is developing at a significant rate, owing to rise in demand for enhanced healthcare services, significant investments by government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries. Various organizations along with government are counselling people regarding the opioid induced constipation (OIC). E-commerce (electronic commerce) has become a vital tool for small and large businesses globally, due to rise in preference of consumers for online shopping over traditional purchasing methods.
The Mu-opioid receptor antagonists’ segment to dominate the market during the forecast period:
In terms of drug type, the Mu-opioid receptor antagonists segment contributed to the largest share of more than half of the global opioid induced constipation (OIC) drugs market in 2021, and is expected to maintain progressive growth during the forecast period. The same segment is projected to witness highest CAGR of 5.5% from 2022 to 2031, owing to rise in the number of product launches by the key players for treating opioid induced constipation (OIC) and the rise in research activities for evaluating safety and efficacy of these agents.
The prescribed drugs segment to rule the roost:
On the basis of prescription type, the prescribed drugs segment contributed to the largest share of more than four-fifths of the global opioid induced constipation (OIC) drugs market revenue, and is expected to retain its dominance by 2031. This is due to the availability of major drugs and rise in number of manufacturing of these formulations by the key players. The over-the-counter drugs segment would portray the fastest CAGR of 6.3% during the forecast period. This is due to rise in adoption of these drugs along with prescribed drugs for opioid induced constipation (OIC) management.
The drug store and retail pharmacies to dominate in terms of revenue during the forecast period:
Based on distribution channel, the drug store and retail pharmacies garnered the highest share in 2021, holding more than half of the global opioid induced constipation (OIC) drugs market revenue, and is expected to retain its dominance by 2031. This is due to increase in preference of the people toward retail pharmacies, as retail pharmacies guide patients regarding medications and usage during treatment period. However, the online providers segment is projected to witness highest CAGR of 9.3%, owing to rise in popularity of online pharmacy and number of users preferring online pharmacies.
North America region garnered the major share in 2021:
By region, North America accounted for the highest share in 2021, holding nearly two-fifths of the global opioid induced constipation (OIC) drugs market revenue, and is projected to rule the roost by 2031. This is owing to the rise in prevalence of opioid induced constipation (OIC) cases, prevalence of advanced healthcare infrastructure and increase in number of key players offering novel therapeutics. The Asia-Pacific region, simultaneously, would portray the fastest CAGR of 6.5% during the forecast period. This is due to increasing number of cancer cases resulting in rise in use of opioids, increase in awareness campaign and rise in investments for development of effective drugs for treating opioid induced constipation (OIC).
Leading Market Players:
- Takeda Pharmaceutical Company Limited
- Mallinckrodt PLC
- Cosmo Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Novartis AG
- Shionogi & Co. Ltd.
- Bausch Health Companies Inc.
- AstraZeneca plc
- Merck & Co. Inc.
★ See What’s Inside This Report @
https://www.alliedmarketresearch.com/purchase-enquiry/13745
About Us:
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides end-to-end solutions along with information, education, advocacy, and networking resources to SMEs and early-stage start-ups to bring excellence to their processes. In addition, we offer a nurturing environment required to develop and grow businesses, including business planning; virtual support; market intelligence; acquiring resources; and getting direct access to finance, suppliers, and other experts to boost the growth of businesses and entrepreneurs.
Our bundled and hassle-free business support systems are customized to meet the needs of SME consultants and industry leaders. Moreover, our large network of skilled consultants and experts help start-ups get the business on a roll.
Contact:
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected]
